Skip to main content

Table 2 Patients’ characteristics and clinicopathological feature in subgroup analysis.

From: Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer

a) Metastatic de-novo versus metastatic recurrent
  Metastatic recurrent (n = 26) Metastatic de-novo (n = 10) P value
Age median (range), (y.o.) 51 (33-74) 49 (35-64) 0.344
Subtype    0.079
 Luminal 19 (73.1%) 10 (100%)  
 Triple negative 7 (26.9%) 0 (0%)  
Number of previous chemotherapy regimens, (n)    0.515
 0 17 (65.4%) 5 (50.0%)  
 1 6 (27.3%) 4 (40.0%)  
 2 1 (3.8%) 1 (10.0%)  
3 2 (7.7%) 0 (0%)  
Previous endocrine therapy, (n) 16 (61.5%) 10 (100%) 0.021
Metastatic sites, (n)    0.473
 Visceral 16 (61.5%) 7 (70.0%)  
 Non-visceral 10 (27.8%) 3 (30.0%)  
b) No prior chemotherapy (CT) versus after chemotherapy.
  No primary CT (n = 22) After CT (n = 14) P value
Age median (range), (y.o.) 51 (34-74) 47 (33-73) 0.243
Metastatic de-novo or recurrent, (n)    0.318
 Metastatic de-novo 5 (22.7%) 5 (35.7%)  
 Metastatic recurrent 17 (77.3%) 9 (64.3%)  
Subtype    0.433
 Luminal 17 (77.3%) 12 (85.7%)  
 Triple negative 5 (22.7%) 2 (14.3%)  
Previous endocrine therapy, (n) 16 (72.7%) 10 (71.4%) 0.611
Metastatic sites, (n)    0.374
 Visceral 15 (68.2%) 8 (57.1%)  
 Non-visceral 7 (31.8%) 6 (42.9%)  
c) Visceral metastasis versus non-visceral metastasis.
  Visceral metastasis (n = 23) Non-visceral metastasis (n = 13) P value
Age median (range), (y.o.) 51.5 (33-73) 48 (34-74) 0.135
Metastatic de-novo or recurrent, (n)    0.473
 Metastatic de-novo 7 (30.4%) 3 (23.1%)  
 Metastatic recurrent 16 (69.6%) 10 (76.9%)  
Subtype    0.499
 Luminal 19 (82.6%) 10 (76.9%)  
 Triple negative 4 (17.4%) 3 (23.1%)  
Number of previous chemotherapy regimens, (n)    0.920
 0 14 (60.9%) 8 (61.5%)  
 1 7 (30.4%) 3 (23.1%)  
 2 1 (4.3%) 1 (7.7%)  
3 1 (4.3%) 1 (7.7%)  
Previous endocrine therapy, (n) 18 (78.3%) 8 (61.5%) 0.420
d) Luminal type versus triple negative breast cancer.
  Luminal (n = 29) TN (n = 7) P value
Age median (range), (y.o.) 50 (33-74) 58 (36-73) 0.219
Metastatic de-novo or recurrent, (n)    0.079
 Metastatic de-novo 10 (22.7%) 0 (35.7%)  
 Metastatic recurrent 19 (77.3%) 7 (64.3%)  
Number of previous chemotherapy regimens, (n)    0.773
 0 17 (60.9%) 5 (61.5%)  
 1 8 (30.4%) 2 (23.1%)  
 2 2 (4.3%) 0 (7.7%)  
3 2 (4.3%) 0 (7.7%)  
Metastatic sites, (n)    0.499
 Visceral 19 (68.2%) 4 (57.1%)  
 Non-visceral 10 (31.8%) 3 (42.9%)  
  Metastatic recurrent (n = 19) Metastatic de-novo (n = 10) P value
Age median (range), (y.o.) 50 (33-74) 49 (35-64) 0.618
Number of previous chemotherapy regimens, (n)    0.510
 0 12 (65.4%) 5 (50.0%)  
 1 4 (27.3%) 4 (40.0%)  
 2 1 (3.8%) 1 (10.0%)  
3 2 (7.7%) 0 (0%)  
Previous endocrine therapy, (n) 15 (61.5%) 10 (100%) 0.163
Metastatic sites, (n)    0.522
 Visceral 12 (61.5%) 7 (70.0%)  
Non-visceral 7 (27.8%) 3 (30.0%)  
\